<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7551028\results\search\disease\results.xml">
  <result pre="Review Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating" exact="Diseases" post="and the COVID-19 Pandemic Outbreak https://orcid.org/0000-0001-6213-6040LowZheng Yao1FaroukIsra Ahmad1https://orcid.org/0000-0003-3548-4853LalSunil Kumar12*[1],"/>
  <result pre="diseases aside from the intended ones. Drug repositioning results in" exact="lower" post="overall developmental expenses and risk assessments, as the efficacy"/>
  <result pre="novel, rare, orphan, and resistant diseases, such as Cushingâ€™s syndrome," exact="HIV infection," post="and pandemic outbreaks such as COVID-19. Repositioning existing drugs"/>
  <result pre="repositioning novel diseases orphan diseases drug personalisation COVID-19 HIV Cushingâ€™s" exact="syndrome" post="1. Introduction Drug development is a lengthy and detailed"/>
  <result pre="on treating diseases by creating specific molecules that target the" exact="disease" post="to alleviate or treat the presenting symptoms. Drug discovery"/>
  <result pre="that targets a particular cellular pathway to treat a particular" exact="disease" post="[1,2]. The process is designed to ensure that a"/>
  <result pre="adherence of patients and reduces side-effects such as nausea, vomiting," exact="high blood pressure," post="irritability, sweating and numbness as it is gradually released"/>
  <result pre="trend, especially for old and established drugs, to seek new" exact="disease" post="targets. The positive projection of drug repositioning lies within"/>
  <result pre="of a repositioned drug; it was first intended to treat" exact="heart" post="disease and can now be used to treat erectile"/>
  <result pre="a repositioned drug; it was first intended to treat heart" exact="disease" post="and can now be used to treat erectile dysfunction."/>
  <result pre="treat heart disease and can now be used to treat" exact="erectile dysfunction." post="Another prime example is Duloxetine, currently the most preferred"/>
  <result pre="is Duloxetine, currently the most preferred drug therapy for stress" exact="urinary incontinence" post="(SUI), where it was initially developed for depression [5]."/>
  <result pre="stress urinary incontinence (SUI), where it was initially developed for" exact="depression" post="[5]. Drug repositioning plays a very crucial role in"/>
  <result pre="costs by approximately $300 million. Also, drug repositioning results in" exact="lower" post="development risk as the safety of the repositioned drugs"/>
  <result pre="approach, the company Celgene successfully repositioned Thalidomide into an effective" exact="cancer" post="drug therapy for multiple myeloma. In the year 2003"/>
  <result pre="successfully repositioned Thalidomide into an effective cancer drug therapy for" exact="multiple myeloma." post="In the year 2003 alone, it successfully captured $271"/>
  <result pre="drug repositioning offers a positive outcome in orphan drug development." exact="Orphan diseases" post="(ODs) are those that affect only a minute population,"/>
  <result pre="drugs used to treat other diseases such as HIV and" exact="malaria" post="are being carefully evaluated as treatments for COVID-19. Multiple"/>
  <result pre="and malaria are being carefully evaluated as treatments for COVID-19." exact="Multiple" post="types of drugs such as antimalarials, antivirals and antibiotics"/>
  <result pre="respect to the â€œsignatureâ€� or unique characteristic of the drug," exact="disease" post="or clinical phenotype [16]. The transcriptomic signature can be"/>
  <result pre="opposite set of gene expression changes, i.e., genes upregulated in" exact="disease" post="are downregulated by the drug, that renders potential in"/>
  <result pre="potential in that drug to be used therapeutically for the" exact="disease" post="[17]. This method has successfully identified and exploited many"/>
  <result pre="the hallmark of a gene expression pattern for a particular" exact="disease" post="phenotype is then very likely to be able to"/>
  <result pre="then very likely to be able to revert the given" exact="disease" post="phenotype. A study conducted by Wei et al. (2006)"/>
  <result pre="the signature of glucocorticoid sensitive profile and successfully reversed the" exact="glucocorticoid resistance" post="in acute lymphoblastic leukaemia cells when screened across the"/>
  <result pre="glucocorticoid sensitive profile and successfully reversed the glucocorticoid resistance in" exact="acute lymphoblastic leukaemia" post="cells when screened across the drug-associated gene expression database."/>
  <result pre="profile and successfully reversed the glucocorticoid resistance in acute lymphoblastic" exact="leukaemia" post="cells when screened across the drug-associated gene expression database."/>
  <result pre="for signatures are yet to be established. For instance, a" exact="central nervous system" post="injury involves 21 genes for signature, based on a"/>
  <result pre="absolute fold change of â‰¥1.5. In contrast, glioblastoma, an aggressive" exact="cancer" post="in the spinal cord or brain can engage up"/>
  <result pre="contrast, glioblastoma, an aggressive cancer in the spinal cord or" exact="brain" post="can engage up to 1000 genes with a p-value"/>
  <result pre="agent, Celecoxib, binds to cadherin-11, a crucial adhesion molecule in" exact="rheumatoid arthritis" post="and poor prognosis malignancies, upon performing high-throughput computational docking"/>
  <result pre="Celecoxib, binds to cadherin-11, a crucial adhesion molecule in rheumatoid" exact="arthritis" post="and poor prognosis malignancies, upon performing high-throughput computational docking"/>
  <result pre="diseases [24]. The construction of GWAS genes associated with the" exact="disease" post="traits involves an extensive database [24]. For instance, the"/>
  <result pre="investigation, they were 991 GWAS genes identified relevant to the" exact="disease" post="traits. The analysed rows of GWAS data that corresponded"/>
  <result pre="For example, the drug Denosumab, which was initially intended for" exact="postmenopausal osteoporosis," post="is now a potential drug candidate for Crohnâ€™s disease"/>
  <result pre="postmenopausal osteoporosis, is now a potential drug candidate for Crohnâ€™s" exact="disease" post="associated with variations in tumour necrosis factor member 11"/>
  <result pre="discovered 184/192 predicted candidate genes as novel therapeutic targets for" exact="coronary artery disease" post="(CAD), and 981/993 potential drugs from the drug databases"/>
  <result pre="184/192 predicted candidate genes as novel therapeutic targets for coronary" exact="artery disease" post="(CAD), and 981/993 potential drugs from the drug databases"/>
  <result pre="predicted candidate genes as novel therapeutic targets for coronary artery" exact="disease" post="(CAD), and 981/993 potential drugs from the drug databases"/>
  <result pre="druggable. Pathway mapping is a network analysis on drug or" exact="disease" post="networks based on gene expression patterns, disease pathology and"/>
  <result pre="on drug or disease networks based on gene expression patterns," exact="disease" post="pathology and protein interaction, providing the necessary information in"/>
  <result pre="unravelling the potential for drug repositioning [24]. A study on" exact="respiratory" post="viral infections conducted by Smith et al. successfully identified"/>
  <result pre="the potential for drug repositioning [24]. A study on respiratory" exact="viral" post="infections conducted by Smith et al. successfully identified 67"/>
  <result pre="potential for drug repositioning [24]. A study on respiratory viral" exact="infections" post="conducted by Smith et al. successfully identified 67 common"/>
  <result pre="identified 67 common biological pathways that may be associated with" exact="respiratory" post="viral infections. Subsequently, crossing these pathways to the DrugBank"/>
  <result pre="67 common biological pathways that may be associated with respiratory" exact="viral" post="infections. Subsequently, crossing these pathways to the DrugBank database,"/>
  <result pre="potential drug repositioning candidates are discovered for the treatment of" exact="respiratory" post="viral infection. One of them is the drug Amrinone,"/>
  <result pre="drug repositioning candidates are discovered for the treatment of respiratory" exact="viral infection." post="One of them is the drug Amrinone, a phosphodiesterase"/>
  <result pre="a phosphodiesterase inhibitor that was used for the treatment of" exact="congestive heart failure" post="[26]. Also, multiple omics analysis mapped to significant pathways"/>
  <result pre="phosphodiesterase inhibitor that was used for the treatment of congestive" exact="heart" post="failure [26]. Also, multiple omics analysis mapped to significant"/>
  <result pre="identified for several diseases such as dengue haemorrhagic fever [27]," exact="head and neck squamous cell carcinoma" post="[28] and rheumatoid arthritis [29] amongst many others, using"/>
  <result pre="for several diseases such as dengue haemorrhagic fever [27], head" exact="and neck" post="squamous cell carcinoma [28] and rheumatoid arthritis [29] amongst"/>
  <result pre="diseases such as dengue haemorrhagic fever [27], head and neck" exact="squamous cell carcinoma" post="[28] and rheumatoid arthritis [29] amongst many others, using"/>
  <result pre="as dengue haemorrhagic fever [27], head and neck squamous cell" exact="carcinoma" post="[28] and rheumatoid arthritis [29] amongst many others, using"/>
  <result pre="fever [27], head and neck squamous cell carcinoma [28] and" exact="rheumatoid arthritis" post="[29] amongst many others, using this approach. However, there"/>
  <result pre="[27], head and neck squamous cell carcinoma [28] and rheumatoid" exact="arthritis" post="[29] amongst many others, using this approach. However, there"/>
  <result pre="it was found that Leflunomide (LEF), a drug for active" exact="rheumatoid arthritis," post="might increase the risk for pancreatic neoplasms upon investigating"/>
  <result pre="for active rheumatoid arthritis, might increase the risk for pancreatic" exact="neoplasms" post="upon investigating the latent factors and compared to KEGG"/>
  <result pre="favourable outcome by combining both approaches on drug repositioning for" exact="hyperuricemia" post="[32]. Hyperuricemia is a disorder where excessive uric acid"/>
  <result pre="DSSTox database and the NCGC Pharmaceutical Collection (NPC) [32]. A" exact="total" post="of 3167 drugs approved for clinical use were sorted"/>
  <result pre="study concluded that Olsalazine Sodium (OS), a drug intended for" exact="acute" post="and chronic ulcerative colitis has massive potential in inhibiting"/>
  <result pre="that Olsalazine Sodium (OS), a drug intended for acute and" exact="chronic" post="ulcerative colitis has massive potential in inhibiting XOD, providing"/>
  <result pre="Olsalazine Sodium (OS), a drug intended for acute and chronic" exact="ulcerative colitis" post="has massive potential in inhibiting XOD, providing a potential"/>
  <result pre="Sodium (OS), a drug intended for acute and chronic ulcerative" exact="colitis" post="has massive potential in inhibiting XOD, providing a potential"/>
  <result pre="known as the ACE-2 cell receptor, found abundantly in the" exact="blood vessels," post="heart and lung AT2 alveolar epithelial cells, subsequently leading"/>
  <result pre="the ACE-2 cell receptor, found abundantly in the blood vessels," exact="heart" post="and lung AT2 alveolar epithelial cells, subsequently leading to"/>
  <result pre="abundantly in the blood vessels, heart and lung AT2 alveolar" exact="epithelial" post="cells, subsequently leading to COVID-19 [39]. The AP2-associated protein"/>
  <result pre="This new development course of repositioning can circumvent the unexpected" exact="derailment" post="due to unforeseen failures during primary preclinical studies [45]."/>
  <result pre="can circumvent the unexpected derailment due to unforeseen failures during" exact="primary" post="preclinical studies [45]. With the established formulations, ADMET (absorption,"/>
  <result pre="tools, making the retrieval of information more accessible [48]. 4." exact="Classic" post="Examples of Repositioned Drugs A notable success in drug"/>
  <result pre="the 1970s, where the drug Minoxidil was approved to treat" exact="hair loss" post="aside from its intended use for the treatment of"/>
  <result pre="with the release of Sildenafil, a repositioned drug to treat" exact="erectile dysfunction" post="aside from the initial indication, angina followed by the"/>
  <result pre="indication, angina followed by the drug, Duloxetine, used for stress" exact="urinary incontinence" post="which was originally intended for major depressive disorder. 4.1."/>
  <result pre="used for stress urinary incontinence which was originally intended for" exact="major depressive disorder." post="4.1. Minoxidil, Farewell to Hair Loss The classic example"/>
  <result pre="is Minoxidil, an oral drug that was intended to treat" exact="hypertension" post="then became a treatment for hair loss prevention [49,50]."/>
  <result pre="was intended to treat hypertension then became a treatment for" exact="hair loss" post="prevention [49,50]. Minoxidil was first introduced in the 1970s/1980s"/>
  <result pre="by the FDA in 1979 as a topical application for" exact="hair loss" post="(androgenic alopecia) treatment [13,52,53]. Its mechanism functioned by causing"/>
  <result pre="vasodilation via the opening of potassium channels, which indirectly upregulated" exact="vascular" post="endothelial growth factor (VEGF) expression in human hair follicle"/>
  <result pre="thereby promoting significant hair growth. 4.2. Sildenafil, New Usage for" exact="Erectile" post="Dysfunction Another prominent repositioned drug is Sildenafil, a phosphodiesterase"/>
  <result pre="promoting significant hair growth. 4.2. Sildenafil, New Usage for Erectile" exact="Dysfunction" post="Another prominent repositioned drug is Sildenafil, a phosphodiesterase type"/>
  <result pre="Erectile Dysfunction Another prominent repositioned drug is Sildenafil, a phosphodiesterase" exact="type 5" post="inhibitor developed by Pfizer, which was initially intended to"/>
  <result pre="was initially intended to treat angina, a condition characterised by" exact="chest" post="pain and discomfort due to underlying heart disease where"/>
  <result pre="to treat angina, a condition characterised by chest pain and" exact="discomfort" post="due to underlying heart disease where one or more"/>
  <result pre="condition characterised by chest pain and discomfort due to underlying" exact="heart" post="disease where one or more coronary arteries are blocked"/>
  <result pre="characterised by chest pain and discomfort due to underlying heart" exact="disease" post="where one or more coronary arteries are blocked or"/>
  <result pre="flow. However, it opened up possibilities for the treatment of" exact="erectile dysfunction" post="when several volunteers experienced a strong, unusual persistent erection"/>
  <result pre="several volunteers experienced a strong, unusual persistent erection upon Sildenafil" exact="consumption" post="[55]. With further studies and trials carried out, Sildenafil"/>
  <result pre="over the counter. It works primarily as a treatment for" exact="erectile dysfunction" post="via the same mode of action by inhibiting phosphodiesterase"/>
  <result pre="dysfunction via the same mode of action by inhibiting phosphodiesterase" exact="type 5" post="AND preventing the breakdown of cyclic guanosine monophosphate (cGMP),"/>
  <result pre="Cymbalta in August 2004. Its prime intention was to treat" exact="major depressive disorder" post="[56]. However, serotonin and norepinephrine are also known to"/>
  <result pre="outcome. The drug can now be used to treat stress" exact="urinary incontinence" post="(SUI), a state portrayed by occasional loss of urine"/>
  <result pre="of pelvic muscles, urinary sphincter or other factors such as" exact="childbirth" post="and prostatectomy. SUI commonly manifests its symptoms during occasions"/>
  <result pre="2010, the drug was approved by the FDA for diabetic" exact="peripheral" post="neuropathic pain (DPNP), fibromyalgia and chronic musculoskeletal pain treatment,"/>
  <result pre="approved by the FDA for diabetic peripheral neuropathic pain (DPNP)," exact="fibromyalgia" post="and chronic musculoskeletal pain treatment, respectively [57,58]. As of"/>
  <result pre="the FDA for diabetic peripheral neuropathic pain (DPNP), fibromyalgia and" exact="chronic" post="musculoskeletal pain treatment, respectively [57,58]. As of the year"/>
  <result pre="than $9 billion in revenue. 4.4. New Hope for Orphan" exact="Disease" post="Drug Development Drug repositioning has paved the path for"/>
  <result pre="path for the development of orphan drugs for orphan diseases." exact="Orphan diseases" post="(ODs) are denoted as a disease with a rare"/>
  <result pre="for orphan diseases. Orphan diseases (ODs) are denoted as a" exact="disease" post="with a rare occurrence, affecting only a small population,"/>
  <result pre="(NPC), in collaboration with NIHâ€™s Therapeutics for Rare and Neglected" exact="Diseases" post="(TRND) [60]. The prime mission of this collaboration is"/>
  <result pre="Food and Drug Administration (FDA) has also established the Rare" exact="Diseases" post="Repurposing Database (RDRD), by matching the FDA orphan database"/>
  <result pre="can heighten to another success. 4.4.1. Korlymâ€™s Legacies on Orphan" exact="Disease" post="Cushingâ€™s syndrome is an orphan disease that affects a"/>
  <result pre="to another success. 4.4.1. Korlymâ€™s Legacies on Orphan Disease Cushingâ€™s" exact="syndrome" post="is an orphan disease that affects a minute population."/>
  <result pre="Korlymâ€™s Legacies on Orphan Disease Cushingâ€™s syndrome is an orphan" exact="disease" post="that affects a minute population. The development of this"/>
  <result pre="disease that affects a minute population. The development of this" exact="disease" post="occurs due to the prolonged exposure to glucocorticoids such"/>
  <result pre="range from excessive weight gain to dreadful acne, constant anxiety," exact="hirsutism" post="and insomnia [65]. The drug Korlym has successfully addressed"/>
  <result pre="excessive weight gain to dreadful acne, constant anxiety, hirsutism and" exact="insomnia" post="[65]. The drug Korlym has successfully addressed this disease."/>
  <result pre="Relacorilant is now also in phase-I clinical trials for hormone-resistant" exact="prostate cancer" post="[67]. 4.4.2. Everolimus on Rare Tuberous Sclerosis Complex Most"/>
  <result pre="is now also in phase-I clinical trials for hormone-resistant prostate" exact="cancer" post="[67]. 4.4.2. Everolimus on Rare Tuberous Sclerosis Complex Most"/>
  <result pre="trials for hormone-resistant prostate cancer [67]. 4.4.2. Everolimus on Rare" exact="Tuberous Sclerosis Complex" post="Most of the rare diseases correspond to orphan disease,"/>
  <result pre="hormone-resistant prostate cancer [67]. 4.4.2. Everolimus on Rare Tuberous Sclerosis" exact="Complex" post="Most of the rare diseases correspond to orphan disease,"/>
  <result pre="always. One of the prime examples of the rare orphan" exact="disease" post="is the Tuberous sclerosis complex [68]. It is a"/>
  <result pre="is the Tuberous sclerosis complex [68]. It is a rare" exact="autosomal dominant" post="genetic disease resulting from the mutations in the TSC1"/>
  <result pre="sclerosis complex [68]. It is a rare autosomal dominant genetic" exact="disease" post="resulting from the mutations in the TSC1 and TSC2"/>
  <result pre="in organs such as the brain, kidneys, skin, lungs, eyes" exact="and heart" post="[71]. These hamartomas can affect the function of many"/>
  <result pre="organs such as the brain, kidneys, skin, lungs, eyes and" exact="heart" post="[71]. These hamartomas can affect the function of many"/>
  <result pre="of many vital organs which result in symptoms including seizures," exact="intellectual disability," post="developmental delay, behavioural problems, skin abnormalities, lung disease, kidney"/>
  <result pre="including seizures, intellectual disability, developmental delay, behavioural problems, skin abnormalities," exact="lung disease," post="kidney disease and even death. Everolimus is a drug"/>
  <result pre="intellectual disability, developmental delay, behavioural problems, skin abnormalities, lung disease," exact="kidney disease" post="and even death. Everolimus is a drug that addresses"/>
  <result pre="disability, developmental delay, behavioural problems, skin abnormalities, lung disease, kidney" exact="disease" post="and even death. Everolimus is a drug that addresses"/>
  <result pre="the use of Everolimus in 2010, and 2012 for TSC-related" exact="subependymal giant cell astrocytoma" post="and renal angiomyolipoma, respectively [72]. This drug successfully helped"/>
  <result pre="Everolimus in 2010, and 2012 for TSC-related subependymal giant cell" exact="astrocytoma" post="and renal angiomyolipoma, respectively [72]. This drug successfully helped"/>
  <result pre="2010, and 2012 for TSC-related subependymal giant cell astrocytoma and" exact="renal angiomyolipoma," post="respectively [72]. This drug successfully helped TSC patients by"/>
  <result pre="manifestation of TSC, such as facial angiofibroma, cardiac rhabdomyomas and" exact="lymphangioleiomyomatosis" post="(LAM) [72]. 5. Promising Novel Uses in Drug Repositioning"/>
  <result pre="intended for sedative purposes is now mainly used for specific" exact="cancer" post="treatments. Together with its derivative Lenalidomide, manufactured by Celgene,"/>
  <result pre="molecules would undergo clinical trials and await FDA approval for" exact="disease" post="treatment. The explored novel uses in drug repositioning has"/>
  <result pre="novel uses in drug repositioning has opened many possibilities on" exact="disease" post="treatment, pulling the gap of treatment and diseases closer"/>
  <result pre="the quality of treatment, especially on highly mutated diseases, novel" exact="disease" post="outbreaks and highly resistant and orphan diseases. 5.1. Novel"/>
  <result pre="resistant and orphan diseases. 5.1. Novel Uses of Zidovudine for" exact="Viral" post="Diseases The development of a drug for highly mutated"/>
  <result pre="and orphan diseases. 5.1. Novel Uses of Zidovudine for Viral" exact="Diseases" post="The development of a drug for highly mutated diseases"/>
  <result pre="of a drug for highly mutated diseases such as Human" exact="Immunodeficiency" post="Virus (HIV) has been an expensive and time-consuming process."/>
  <result pre="1960s specifically targeting the Friend Leukaemia Virus (FV) that causes" exact="leukaemia" post="has been successfully repositioned to be an antiretroviral drug"/>
  <result pre="for HIV as it is often regarded as an incurable" exact="chronic" post="disease [77,78]. For example, it was discovered that two"/>
  <result pre="HIV as it is often regarded as an incurable chronic" exact="disease" post="[77,78]. For example, it was discovered that two current"/>
  <result pre="important to eradicate multitudinous highly resistant diseases such as metronidazole-resistant" exact="Giardia" post="Lamblia, which accommodated up to 20% of the treatment"/>
  <result pre="of the treatment failure cases [68]. Giardiasis is an uncommon" exact="disease" post="that affects millions of people, especially in developing countries"/>
  <result pre="especially in developing countries where it can be transmitted via" exact="foodborne illness" post="or person-to-person transmission [68]. Auranofin, an antirheumatic drug approved"/>
  <result pre="Auranofin such as diarrhoea, vomiting, abdominal cramps and symptoms of" exact="hypersensitivity" post="moved interest away from that particular drug. However, in"/>
  <result pre="thioredoxin oxidoreductase, a crucial enzyme to counter oxidative damage in" exact="Giardia" post="Lamblia [68]. Apart from that, Auranofin has also shown"/>
  <result pre="machinery, incorporate its RNA into the cell and produce its" exact="viral" post="proteins to assemble and release [79]. According to Lewis"/>
  <result pre="According to Lewis et al., Auranofin notably reduces the cell-associated" exact="viral" post="DNA reservoir and induces cell death, especially on memory"/>
  <result pre="developed. Among the significant challenges during the global fight against" exact="infectious diseases" post="are the unpredictable emergence of disease and the lack"/>
  <result pre="global fight against infectious diseases are the unpredictable emergence of" exact="disease" post="and the lack of therapeutics for uncommon diseases. The"/>
  <result pre="uncommon diseases. The most recent example is the novel coronavirus" exact="disease" post="(COVID-19) which arose in 2019, affecting over 17,700,000 individuals"/>
  <result pre="the need of treatment [83]. COVID-19 is caused by severe" exact="acute" post="respiratory syndrome Coronavirus 2 (SARS-CoV-2), a positive-strand single-stranded RNA"/>
  <result pre="need of treatment [83]. COVID-19 is caused by severe acute" exact="respiratory" post="syndrome Coronavirus 2 (SARS-CoV-2), a positive-strand single-stranded RNA virus"/>
  <result pre="of treatment [83]. COVID-19 is caused by severe acute respiratory" exact="syndrome" post="Coronavirus 2 (SARS-CoV-2), a positive-strand single-stranded RNA virus with"/>
  <result pre="have 14 open reading frames (ORFs) that encode for 27" exact="viral" post="proteins [85]. The most prominent viral protein in the"/>
  <result pre="that encode for 27 viral proteins [85]. The most prominent" exact="viral" post="protein in the structure of SARS-CoV-2 is the spike"/>
  <result pre="for its large role in host cell membrane fusion and" exact="viral" post="entry. Other SARS-CoV-2 structural proteins include the matrix protein"/>
  <result pre="cell transcription and translation mechanisms for replication and production of" exact="viral" post="proteins. Drug repositioning has played a large role in"/>
  <result pre="are now exploring the potential of antiviral drugs for other" exact="viral" post="diseases to be used for COVID-19. Two HIV protease"/>
  <result pre="single treatment of Ivermectin expressed a significant reduction in SARS-CoV-2" exact="viral" post="load in a 48-h cell culture environment [90]. More"/>
  <result pre="for COVID-19 [91]. In more severe cases of COVID-19, severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) develops. To combat this"/>
  <result pre="COVID-19 [91]. In more severe cases of COVID-19, severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) develops. To combat this condition,"/>
  <result pre="[91]. In more severe cases of COVID-19, severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) develops. To combat this condition, additional"/>
  <result pre="inhibitors of RbRp and may result in the reduction of" exact="infection" post="severity. Multiple software were used to validate the RdRp"/>
  <result pre="RbRp and may result in the reduction of infection severity." exact="Multiple" post="software were used to validate the RdRp model. These"/>
  <result pre="as HCQ sulphate have been reported to reduce inflammation in" exact="autoimmune diseases" post="[95]. Such information ignited interest in the potential of"/>
  <result pre="of action of CQ against malaria, which was the original" exact="disease" post="it was produced for. In addition, current research and"/>
  <result pre="to be fully discovered, especially in the context of this" exact="viral" post="outbreak. The classical mechanism of action for CQ as"/>
  <result pre="Heme residues [96]. Plasmodium falciparum is a parasite that causes" exact="malaria" post="disease in humans. For this parasite to grow whilst"/>
  <result pre="residues [96]. Plasmodium falciparum is a parasite that causes malaria" exact="disease" post="in humans. For this parasite to grow whilst living"/>
  <result pre="are always required. CQ has been reported previously to block" exact="virus infection" post="in a few ways such as through increasing the"/>
  <result pre="always required. CQ has been reported previously to block virus" exact="infection" post="in a few ways such as through increasing the"/>
  <result pre="provide an explanation on the role of CQ in a" exact="viral" post="life cycle, which supports its candidature potential to be"/>
  <result pre="suggesting that it has little or no effect on many" exact="acute" post="viral diseases such as influenza, dengue, Ebola, HIV and"/>
  <result pre="that it has little or no effect on many acute" exact="viral" post="diseases such as influenza, dengue, Ebola, HIV and Nipah"/>
  <result pre="their discussion, it was highlighted that in the case of" exact="Hepatitis" post="C infection, HCQ used in combination with pegylated interferon"/>
  <result pre="and ribavirin resulted in a positive effect on reducing the" exact="viral" post="load [99]. In vitro studies are now being performed"/>
  <result pre="the drugs, ribavirin, and CQ showed excellent potential in blocking" exact="virus infection" post="at low drug micromolar concentrations. Another study recommends the"/>
  <result pre="drugs, ribavirin, and CQ showed excellent potential in blocking virus" exact="infection" post="at low drug micromolar concentrations. Another study recommends the"/>
  <result pre="time as it has exhibited efficiency in treating COVID-19 associated" exact="pneumonia" post="presented in patients. In addition, CQ has been considered"/>
  <result pre="sulphate has been studied for its antiviral effect on SARS-CoV-2" exact="infection" post="and has been compared with CQ alone for cytotoxicity"/>
  <result pre="been compared with CQ alone for cytotoxicity in vitro using" exact="African" post="green monkey kidney VeroE6 cells [87]. This study has"/>
  <result pre="successfully shown that HCQ sulphate is effective in inhibiting SARS-CoV-2" exact="infection" post="and may be a better option for consideration in"/>
  <result pre="observed in virus titres of nasal washes, stool specimens and" exact="respiratory" post="tissues when compared to other treatments or phosphate-buffered saline"/>
  <result pre="combination of these two drugs is associated with more efficient" exact="viral" post="load reduction and disappearance of COVID-19 in twenty patients"/>
  <result pre="or obtained from many sources such as aberrations in genetics," exact="infectious diseases," post="degenerative disease and more. Diseases often involve many complex"/>
  <result pre="many sources such as aberrations in genetics, infectious diseases, degenerative" exact="disease" post="and more. Diseases often involve many complex cellular pathway"/>
  <result pre="as aberrations in genetics, infectious diseases, degenerative disease and more." exact="Diseases" post="often involve many complex cellular pathway cascades, which can"/>
  <result pre="substantially in different gene profiles due to heterogeneity in human" exact="disease" post="[109]. To reduce the lack of drug efficacy, drug"/>
  <result pre="that aims for maximum tolerated doses. For instance, non-small cell" exact="lung cancer" post="(NSCLC) accounts for 85â€&quot;90% of all lung cancers [110]."/>
  <result pre="aims for maximum tolerated doses. For instance, non-small cell lung" exact="cancer" post="(NSCLC) accounts for 85â€&quot;90% of all lung cancers [110]."/>
  <result pre="portions of echinoderm microtubule-associated protein-like 4 genes (EML4) and anaplastic" exact="lymphoma" post="kinase gene (ALK) in âˆ¼7% of patients with NSCLC."/>
  <result pre="of patients with NSCLC. This was different from the common" exact="NSCLC" post="with epidermal growth factor receptor mutation. Crizotinib, a small-molecule"/>
  <result pre="lymphoma, is now repositioned to treat this small subset of" exact="NSCLC" post="[81]. Without the advance screening of biomarkers in each"/>
  <result pre="NSCLC [81]. Without the advance screening of biomarkers in each" exact="NSCLC" post="individual, this small subset would not be successfully discovered,"/>
  <result pre="EGFR tyrosine kinase inhibitors would have been prescribed to all" exact="NSCLC" post="patients albeit the limited efficacy in patients with EML4-ALK"/>
  <result pre="would have been prescribed to all NSCLC patients albeit the" exact="limited" post="efficacy in patients with EML4-ALK alteration. Recently, the drug"/>
  <result pre="successfully obtained FDA approval as a treatment for patients with" exact="NSCLC" post="with MET exon 14 skipping which occurs in approximately"/>
  <result pre="MET exon 14 skipping which occurs in approximately 3% of" exact="NSCLC" post="tumours and ROS 1/anaplastic lymphoma kinase-positive resistant systemic anaplastic"/>
  <result pre="exon 14 skipping which occurs in approximately 3% of NSCLC" exact="tumours" post="and ROS 1/anaplastic lymphoma kinase-positive resistant systemic anaplastic large"/>
  <result pre="occurs in approximately 3% of NSCLC tumours and ROS 1/anaplastic" exact="lymphoma" post="kinase-positive resistant systemic anaplastic large cell lymphoma (ROS-1/ALK-ALCL) [111]."/>
  <result pre="3% of NSCLC tumours and ROS 1/anaplastic lymphoma kinase-positive resistant" exact="systemic" post="anaplastic large cell lymphoma (ROS-1/ALK-ALCL) [111]. Hence, repositioning the"/>
  <result pre="of NSCLC tumours and ROS 1/anaplastic lymphoma kinase-positive resistant systemic" exact="anaplastic large cell lymphoma" post="(ROS-1/ALK-ALCL) [111]. Hence, repositioning the drug based on stratification"/>
  <result pre="and ROS 1/anaplastic lymphoma kinase-positive resistant systemic anaplastic large cell" exact="lymphoma" post="(ROS-1/ALK-ALCL) [111]. Hence, repositioning the drug based on stratification"/>
  <result pre="discovers any new processes, machines or new compounds but not" exact="limited" post="to new formulations, recipes or materials for 20 years"/>
  <result pre="acetate and the immunosuppressant Cyclosporine A for the treatment of" exact="allergic conjunctivitis" post="[63]. Apart from this, the lack of participation and"/>
  <result pre="and the immunosuppressant Cyclosporine A for the treatment of allergic" exact="conjunctivitis" post="[63]. Apart from this, the lack of participation and"/>
  <result pre="drug repositioning was mostly initiated by companies other than the" exact="primary" post="inventor [110]. For example, Thalidomide, a complete failure in"/>
  <result pre="other than the primary inventor [110]. For example, Thalidomide, a" exact="complete" post="failure in drug development history was brought back to"/>
  <result pre="brought back to life by the company Celgene to treat" exact="Multiple" post="Myeloma Nodosum Leprosum and Erythema with the exclusion of"/>
  <result pre="back to life by the company Celgene to treat Multiple" exact="Myeloma" post="Nodosum Leprosum and Erythema with the exclusion of pregnant"/>
  <result pre="to take up the aforementioned risk, which, to date, is" exact="limited" post="[112]. Besides that, it is especially difficult to obtain"/>
  <result pre="failed. A kinase inhibitor, Bevacizumab, which was, developed to treat" exact="gastric cancer," post="failed to show efficacy in phase III trials despite"/>
  <result pre="Thalidomide, where a safe development resulted in new hope for" exact="multiple myeloma" post="and brought in revenue of $271 million USD. Also,"/>
  <result pre="where a safe development resulted in new hope for multiple" exact="myeloma" post="and brought in revenue of $271 million USD. Also,"/>
  <result pre="attained enhanced activity as compared to their initial development for" exact="epilepsy" post="and hyperactive disorder, respectively. Orphan diseases such as Cushingâ€™s"/>
  <result pre="to their initial development for epilepsy and hyperactive disorder, respectively." exact="Orphan diseases" post="such as Cushingâ€™s syndrome and TSC obtained promising treatments"/>
  <result pre="epilepsy and hyperactive disorder, respectively. Orphan diseases such as Cushingâ€™s" exact="syndrome" post="and TSC obtained promising treatments through the repositioned drugs"/>
  <result pre="repositioning potential of existing drugs which yield significant alleviation in" exact="disease" post="symptoms. In the current quest for a cure, a"/>
  <result pre="genome-wide association studies for drug repositioningNat. Biotechnol.20123031732010.1038/nbt.215122491277 25.GroverM.BallouzS.MohanasundaramK.GeorgeR.GoscinskiA.CrowleyT.ShermanC.WoutersM.Novel therapeutics for" exact="coronary artery disease" post="from genome-wide association study dataBMC Med. Genom.2015810.1186/1755-8794-8-S2-S1 26.SmithS.DampierW.TozerenA.BrownJ.Magid-SlavM.Identification of"/>
  <result pre="association studies for drug repositioningNat. Biotechnol.20123031732010.1038/nbt.215122491277 25.GroverM.BallouzS.MohanasundaramK.GeorgeR.GoscinskiA.CrowleyT.ShermanC.WoutersM.Novel therapeutics for coronary" exact="artery disease" post="from genome-wide association study dataBMC Med. Genom.2015810.1186/1755-8794-8-S2-S1 26.SmithS.DampierW.TozerenA.BrownJ.Magid-SlavM.Identification of"/>
  <result pre="studies for drug repositioningNat. Biotechnol.20123031732010.1038/nbt.215122491277 25.GroverM.BallouzS.MohanasundaramK.GeorgeR.GoscinskiA.CrowleyT.ShermanC.WoutersM.Novel therapeutics for coronary artery" exact="disease" post="from genome-wide association study dataBMC Med. Genom.2015810.1186/1755-8794-8-S2-S1 26.SmithS.DampierW.TozerenA.BrownJ.Magid-SlavM.Identification of"/>
  <result pre="Genom.2015810.1186/1755-8794-8-S2-S1 26.SmithS.DampierW.TozerenA.BrownJ.Magid-SlavM.Identification of Common Biological Pathways and Drug Targets Across" exact="Multiple" post="Respiratory Viruses Based on Human Host Gene Expression AnalysisPLoS"/>
  <result pre="26.SmithS.DampierW.TozerenA.BrownJ.Magid-SlavM.Identification of Common Biological Pathways and Drug Targets Across Multiple" exact="Respiratory" post="Viruses Based on Human Host Gene Expression AnalysisPLoS ONE20127e3317410.1371/journal.pone.003317422432004"/>
  <result pre="by integrating multiple omics analysesSci. Rep.2019910.1038/s41598-018-36636-1 28.WeiG.GaoL.TangZ.LinP.LiangL.ZengJ.ChenG.ZhangL.Drug repositioning in head" exact="and neck" post="squamous cell carcinoma: An integrated pathway analysis based on"/>
  <result pre="multiple omics analysesSci. Rep.2019910.1038/s41598-018-36636-1 28.WeiG.GaoL.TangZ.LinP.LiangL.ZengJ.ChenG.ZhangL.Drug repositioning in head and neck" exact="squamous cell" post="carcinoma: An integrated pathway analysis based on connectivity map"/>
  <result pre="receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid" exact="arthritis" post="drugArthritis Res. Ther.20202210.1186/s13075-020-2097-2 30.QuX.RajpalD.Applications of Connectivity Map in drug"/>
  <result pre="or Zidovudine in three-drug combination therapy for initial treatment of" exact="HIV infection" post="in antiretroviral-naÃ¯ve individualsCochrane Database Syst. Rev.201010.1002/14651858.CD008651 38.WenM.ZhangZ.NiuS.ShaH.YangR.YunY.LuH.Deep-Learning-Based Drugâ€&quot;Target Interaction"/>
  <result pre="Zidovudine in three-drug combination therapy for initial treatment of HIV" exact="infection" post="in antiretroviral-naÃ¯ve individualsCochrane Database Syst. Rev.201010.1002/14651858.CD008651 38.WenM.ZhangZ.NiuS.ShaH.YangR.YunY.LuH.Deep-Learning-Based Drugâ€&quot;Target Interaction"/>
  <result pre="Interaction PredictionJ. Proteome Res.2017161401140910.1021/acs.jproteome.6b0061828264154 39.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV" exact="acute" post="respiratory diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 40.VelavanT.MeyerC.The COVID-19 epidemicTrop. Med. Int. Health20202527828010.1111/tmi.1338332052514 41.NishimuraY.HaraH.Editorial:"/>
  <result pre="PredictionJ. Proteome Res.2017161401140910.1021/acs.jproteome.6b0061828264154 39.RichardsonP.GriffinI.TuckerC.SmithD.OechsleO.PhelanA.StebbingJ.Baricitinib as potential treatment for 2019-nCoV acute" exact="respiratory" post="diseaseLancet2020395e30e3110.1016/S0140-6736(20)30304-432032529 40.VelavanT.MeyerC.The COVID-19 epidemicTrop. Med. Int. Health20202527828010.1111/tmi.1338332052514 41.NishimuraY.HaraH.Editorial: Drug"/>
  <result pre="and information visualisation for drug repurposingBrief. Bioinform.20111235736810.1093/bib/bbr00521712342 49.DevineB.FifeR.TrustP.Minoxidil for severe" exact="hypertension" post="after failure of other hypotensive drugsBMJ1977266766910.1136/bmj.2.6088.667902045 50.IshidaJ.KonishiM.EbnerN.SpringerJ.Repurposing of approved"/>
  <result pre="hypertension after failure of other hypotensive drugsBMJ1977266766910.1136/bmj.2.6088.667902045 50.IshidaJ.KonishiM.EbnerN.SpringerJ.Repurposing of approved" exact="cardiovascular" post="drugsJ. Transl. Med.20161411510.1186/s12967-016-1031-526727970 51.Camacho-MartÃ­nezF.Hair Loss in WomenSemin. Cutan. Med."/>
  <result pre="on hair growthBr. J. Dermatol.200415018619410.1111/j.1365-2133.2004.05785.x14996087 54.RogersN.AvramM.Medical treatments for male and" exact="female" post="pattern hair lossJ. Am. Acad. Dermatol.20085954756610.1016/j.jaad.2008.07.00118793935 55.RenaudR.XuerebH.Erectile-dysfunction therapiesNat. Rev."/>
  <result pre="Drug RepositioningAnnu. Rep. Med. Chem.20114638540110.1016/B978-0-12-386009-5.00004-7 58.SmithH.S.SmithE.J.SmithB.R.Duloxetine in the management of" exact="chronic" post="musculoskeletal painTher. Clin. Risk Manag.2012826710.2147/TCRM.S1742822767991 59.DunoyerM.Accelerating access to treatments"/>
  <result pre="successful drug repositioningDrug Discov. Today2016211189119510.1016/j.drudis.2016.05.01527240777 65.NishiokaH.YamadaS.Cushingâ€™sâ€™s DiseaseJ. Clin. Med.20198195110.3390/jcm8111951 66.TerzoloM.IacuanielloD.PiaA.AdrianoP.MoraitisA.PivonelloR.SUN-463" exact="Tumor" post="Shrinkage with Preoperative Relacorilant Therapy in Two Patients with"/>
  <result pre="Shrinkage with Preoperative Relacorilant Therapy in Two Patients with Cushingâ€™s" exact="Disease" post="Due to Pituitary MacroadenomasJ. Endocr. Soc.2019310.1210/js.2019-SUN-463 67.MollicaV.Di NunnoV.CimadamoreA.Lopez-BeltranA.ChengL.SantoniM.ScarpelliM.MontironiR.MassariF.Molecular Mechanisms"/>
  <result pre="Relacorilant Therapy in Two Patients with Cushingâ€™s Disease Due to" exact="Pituitary" post="MacroadenomasJ. Endocr. Soc.2019310.1210/js.2019-SUN-463 67.MollicaV.Di NunnoV.CimadamoreA.Lopez-BeltranA.ChengL.SantoniM.ScarpelliM.MontironiR.MassariF.Molecular Mechanisms Related to Hormone"/>
  <result pre="MacroadenomasJ. Endocr. Soc.2019310.1210/js.2019-SUN-463 67.MollicaV.Di NunnoV.CimadamoreA.Lopez-BeltranA.ChengL.SantoniM.ScarpelliM.MontironiR.MassariF.Molecular Mechanisms Related to Hormone Inhibition" exact="Resistance" post="in Prostate CancerCells201984310.3390/cells8010043 68.Tejman-YardenN.MiyamotoY.LeitschD.SantiniJ.DebnathA.GutJ.McKerrowJ.ReedS.EckmannL.A Reprofiled Drug, Auranofin, Is Effective"/>
  <result pre="Prostate CancerCells201984310.3390/cells8010043 68.Tejman-YardenN.MiyamotoY.LeitschD.SantiniJ.DebnathA.GutJ.McKerrowJ.ReedS.EckmannL.A Reprofiled Drug, Auranofin, Is Effective against Metronidazole-Resistant" exact="Giardia" post="lambliaAntimicrob. Agents Chemother.2013572029203510.1128/AAC.01675-1223403423 69.CuratoloP.BombardieriR.JozwiakS.Tuberous sclerosisLancet200837265766810.1016/S0140-6736(08)61279-918722871 70.OsborneJ.FryerA.WebbD.Epidemiology of Tuberous SclerosisAnn."/>
  <result pre="Acad. Sci.199161512512710.1111/j.1749-6632.1991.tb37754.x2039137 71.BisslerJ.KingswoodJ.RadzikowskaE.ZonnenbergB.BelousovaE.FrostM.SauterM.BrakemeierS.de VriesP.BerkowitzN.et al.Everolimus long-term use in patients with" exact="tuberous sclerosis" post="complex: Four-year update of the EXIST-2 studyPLoS ONE201712e018093910.1371/journal.pone.018093928792952 72.FranzD.CapalJ.Profile"/>
  <result pre="EXIST-2 studyPLoS ONE201712e018093910.1371/journal.pone.018093928792952 72.FranzD.CapalJ.Profile of Everolimus in the treatment of" exact="tuberous sclerosis" post="complex: An evidence-based review of its place in therapyNeuropsychiatr."/>
  <result pre="Mutations in the Reverse Transcriptase and Overlapping Surface Genes of" exact="Hepatitis" post="B Virus (HBV) in Treatment-NaÃ¯ve Indonesian HBV CarriersJpn. J."/>
  <result pre="approachAsian J. Sci. Technol.20191099789984 79.LewisM.DaFonsecaS.ChomontN.PalamaraA.TardugnoM.MaiA.CollinsM.WagnerW.Yalley-OgunroJ.GreenhouseJ.et al.Gold drug auranofin restricts the" exact="viral" post="reservoir in the monkey AIDS model and induces containment"/>
  <result pre="reservoir in the monkey AIDS model and induces containment of" exact="viral" post="load following ART suspensionAIDS2011251347135610.1097/QAD.0b013e328347bd7721505294 80.GoenkaS.SimonS.Organogold drug Auranofin exhibits anti-melanogenic"/>
  <result pre="80.GoenkaS.SimonS.Organogold drug Auranofin exhibits anti-melanogenic activity in B16F10 and MNT-1" exact="melanoma" post="cellsArch. Dermatol. Res.201931221322110.1007/s00403-019-01974-131501921 81.ShawA.YasothanU.KirkpatrickP.CrizotinibNat. Rev. Drug Discov.20111089789810.1038/nrd360022129984 82.Worldometers Coronavirus"/>
  <result pre="less toxic derivative of Chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="In VitroCell Discov.2020610.1038/s41421-020-0156-032194981 88.HarrisonC.Coronavirus puts drug repurposing on the"/>
  <result pre="Med. Chem.2006492845284910.1021/jm060185616640347 95.ParkS.YuK.KimY.KimS.KimE.KimS.KimE.CaselM.RollonR.JangS.et al.Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2" exact="Infection" post="in FerretsmBio20201111010.1128/mBio.01114-2032444382 96.SlaterA.Chloroquine: Mechanism of drug action and resistance"/>
  <result pre="Sci. USA199693118651187010.1073/pnas.93.21.118658876229 98.VincentM.BergeronE.BenjannetS.EricksonB.RollinP.KsiazekT.SeidahN.NicholS.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.200526910.1186/1743-422X-2-6916115318 99.HelalG.GadM.Abd-EllahM.EidM.Hydroxychloroquine augments early virological response to"/>
  <result pre="early virological response to pegylated interferon plus ribavirin in genotype-4" exact="chronic hepatitis C" post="patientsJ. Med. Virol.2016882170217810.1002/jmv.2457527183377 100.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.In Vitro Antiviral Activity and"/>
  <result pre="virological response to pegylated interferon plus ribavirin in genotype-4 chronic" exact="hepatitis C" post="patientsJ. Med. Virol.2016882170217810.1002/jmv.2457527183377 100.YaoX.YeF.ZhangM.CuiC.HuangB.NiuP.LiuX.ZhaoL.DongE.SongC.et al.In Vitro Antiviral Activity and"/>
  <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.20201810.1093/cid/ciaa237 101.FrieK.GbinigieK.Chloroquine"/>
  <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.20201810.1093/cid/ciaa237 101.FrieK.GbinigieK.Chloroquine and"/>
  <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.20201810.1093/cid/ciaa237 101.FrieK.GbinigieK.Chloroquine and Hydroxychloroquine:"/>
  <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.20201810.1093/cid/ciaa237 101.FrieK.GbinigieK.Chloroquine and Hydroxychloroquine: Current"/>
  <result pre="online: https://www.cebm.net/covid-19/chloroquine-and-hydroxychloroquine-current-evidence-for-their-effectiveness-in-treating-covid-19/(accessed on 6 March 2020) 102.SavarinoA.BoelaertJ.CassoneA.MajoriG.CaudaR.Effects of Chloroquine on" exact="viral" post="infections: An old drug against todayâ€™s diseasesLancet Infect. Dis.2003372272710.1016/S1473-3099(03)00806-514592603"/>
  <result pre="in patients (pts) with advanced MET exon 14-altered non-small cell" exact="lung cancer" post="(NSCLC)J. Clin. Oncol.20163410810.1200/JCO.2016.34.15_suppl.108 112.NovacN.Challenges and opportunities of drug repositioningTrends"/>
  <result pre="patients (pts) with advanced MET exon 14-altered non-small cell lung" exact="cancer" post="(NSCLC)J. Clin. Oncol.20163410810.1200/JCO.2016.34.15_suppl.108 112.NovacN.Challenges and opportunities of drug repositioningTrends"/>
  <result pre="of competitorsDrug Discov. Today2014191841184710.1016/j.drudis.2014.09.01625269415 114.StewartA.How Thalidomide Works Against CancerScience201434325625710.1126/science.124954324436409 115.KimH.OhS.Novel" exact="Systemic" post="Therapies for Advanced Gastric CancerJ. Gastric Cancer20181811910.5230/jgc.2018.18.e329629216 Figure 1"/>
  <result pre="Today2014191841184710.1016/j.drudis.2014.09.01625269415 114.StewartA.How Thalidomide Works Against CancerScience201434325625710.1126/science.124954324436409 115.KimH.OhS.Novel Systemic Therapies for" exact="Advanced" post="Gastric CancerJ. Gastric Cancer20181811910.5230/jgc.2018.18.e329629216 Figure 1 A summary of"/>
  <result pre="their new roles. Drug Original Medication Repositioned Medication References Auranofin" exact="Rheumatoid arthritis" post="Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell"/>
  <result pre="new roles. Drug Original Medication Repositioned Medication References Auranofin Rheumatoid" exact="arthritis" post="Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell"/>
  <result pre="Medication References Auranofin Rheumatoid arthritis Metronidazole resistant Giardiasis [68] Crizotinib" exact="Anaplastic large-cell lymphoma" post="Non-small-cell lung cancer (NSCLC) [81] Duloxetine Major depressive disorder"/>
  <result pre="Auranofin Rheumatoid arthritis Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell" exact="lymphoma" post="Non-small-cell lung cancer (NSCLC) [81] Duloxetine Major depressive disorder"/>
  <result pre="arthritis Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell" exact="lung cancer" post="(NSCLC) [81] Duloxetine Major depressive disorder Stress Urinary Incontinence"/>
  <result pre="Metronidazole resistant Giardiasis [68] Crizotinib Anaplastic large-cell lymphoma Non-small-cell lung" exact="cancer" post="(NSCLC) [81] Duloxetine Major depressive disorder Stress Urinary Incontinence"/>
  <result pre="of artificial cardiac stents Tuberous sclerosis complex [22] [72] Korlym" exact="Abortion" post="Cushingâ€™s Syndrome [66] Minoxidil Hypertension Androgenic alopecia (Hair loss)"/>
  <result pre="cardiac stents Tuberous sclerosis complex [22] [72] Korlym Abortion Cushingâ€™s" exact="Syndrome" post="[66] Minoxidil Hypertension Androgenic alopecia (Hair loss) [51] Sildenafil"/>
  <result pre="sclerosis complex [22] [72] Korlym Abortion Cushingâ€™s Syndrome [66] Minoxidil" exact="Hypertension" post="Androgenic alopecia (Hair loss) [51] Sildenafil Angina, chest pain/discomfort"/>
  <result pre="[22] [72] Korlym Abortion Cushingâ€™s Syndrome [66] Minoxidil Hypertension Androgenic" exact="alopecia" post="(Hair loss) [51] Sildenafil Angina, chest pain/discomfort Erectile Dysfunction"/>
  <result pre="[66] Minoxidil Hypertension Androgenic alopecia (Hair loss) [51] Sildenafil Angina," exact="chest" post="pain/discomfort Erectile Dysfunction [55] Thalidomide Morning sickness pregnant women"/>
  <result pre="Hypertension Androgenic alopecia (Hair loss) [51] Sildenafil Angina, chest pain/discomfort" exact="Erectile" post="Dysfunction [55] Thalidomide Morning sickness pregnant women Multiple myelomas"/>
  <result pre="Androgenic alopecia (Hair loss) [51] Sildenafil Angina, chest pain/discomfort Erectile" exact="Dysfunction" post="[55] Thalidomide Morning sickness pregnant women Multiple myelomas [13]"/>
  <result pre="chest pain/discomfort Erectile Dysfunction [55] Thalidomide Morning sickness pregnant women" exact="Multiple" post="myelomas [13] Zidovudine Anticancer agent Antiretroviral agent-HIV [75] viruses-12-01058-t002_Table"/>
  <result pre="medication Side-effects may arise with toxic dosage for patients with" exact="cardiovascular" post="disorders Excessive prolong in QTc intervals which leads to"/>
  <result pre="in QTc intervals which leads to ventricular arrhythmias Gastrointestinal upset" exact="Retinal" post="toxicity and myopathy Impairs replication of virus by interfering"/>
  <result pre="intervals which leads to ventricular arrhythmias Gastrointestinal upset Retinal toxicity" exact="and myopathy" post="Impairs replication of virus by interfering with endosome-mediated viral"/>
  <result pre="which leads to ventricular arrhythmias Gastrointestinal upset Retinal toxicity and" exact="myopathy" post="Impairs replication of virus by interfering with endosome-mediated viral"/>
  <result pre="and myopathy Impairs replication of virus by interfering with endosome-mediated" exact="viral" post="entry or other pH-dependent viral replication steps Currently ongoing"/>
  <result pre="virus by interfering with endosome-mediated viral entry or other pH-dependent" exact="viral" post="replication steps Currently ongoing [101,102] Favipiravir Broad-spectrum inhibitor of"/>
  <result pre="viral replication steps Currently ongoing [101,102] Favipiravir Broad-spectrum inhibitor of" exact="viral" post="RNA, i.e., Influenza Raises serum uric acid Diarrhoea Inhibits"/>
  <result pre="viral RNA, i.e., Influenza Raises serum uric acid Diarrhoea Inhibits" exact="viral" post="RbRp in the genome replication process currently ongoing [23,89,103]"/>
  <result pre="agent Not reported for COVID-19. Predicted as: Nausea, rashes, dizziness" exact="Fever" post="and tachycardia Nuclear transport inhibitory activity of viral proteins"/>
  <result pre="rashes, dizziness Fever and tachycardia Nuclear transport inhibitory activity of" exact="viral" post="proteins In vitro studies [90,104] Remdesivir Antiviral activity against"/>
  <result pre="activity against RNA viruses, i.e., Ebola virus Abnormal liver function" exact="Renal" post="impairment Hypotension, diarrhoea and rashes Acts as RbRp inhibitor"/>
  <result pre="Hypotension, diarrhoea and rashes Acts as RbRp inhibitor to target" exact="viral" post="genome replication process Currently ongoing [105,106,107] Baricitinib An orally"/>
  <result pre="potential anti-inflammatory, immunomodulating and antineoplastic activities. Typically used to treat" exact="autoimmune" post="disorders such as rheumatoid arthritis. Not reported for COVID-19."/>
  <result pre="antineoplastic activities. Typically used to treat autoimmune disorders such as" exact="rheumatoid arthritis." post="Not reported for COVID-19. Previous original indication. Nausea Blurred"/>
  <result pre="indication. Nausea Blurred vision Cold sores Shingles Possible increase in" exact="upper respiratory tract infection" post="Hypercholesterolemia Hypertension Urinary tract infection A high-affinity NAK inhibitor,"/>
  <result pre="Nausea Blurred vision Cold sores Shingles Possible increase in upper" exact="respiratory" post="tract infection Hypercholesterolemia Hypertension Urinary tract infection A high-affinity"/>
  <result pre="vision Cold sores Shingles Possible increase in upper respiratory tract" exact="infection" post="Hypercholesterolemia Hypertension Urinary tract infection A high-affinity NAK inhibitor,"/>
  <result pre="Cold sores Shingles Possible increase in upper respiratory tract infection" exact="Hypercholesterolemia" post="Hypertension Urinary tract infection A high-affinity NAK inhibitor, especially"/>
  <result pre="sores Shingles Possible increase in upper respiratory tract infection Hypercholesterolemia" exact="Hypertension" post="Urinary tract infection A high-affinity NAK inhibitor, especially on"/>
  <result pre="increase in upper respiratory tract infection Hypercholesterolemia Hypertension Urinary tract" exact="infection" post="A high-affinity NAK inhibitor, especially on AP2-associated protein kinase"/>
  <result pre="1 (AAK1), a pivotal regulator of clathrin-mediated endocytosis involved in" exact="viral" post="entry at the lungs Currently ongoing [39,108]"/>
 </snippets>
</snippetsTree>
